Intranasally administered serelaxin abrogates airway remodelling and attenuates airway hyperresponsiveness in allergic airways disease

Clinical and Experimental Allergy

Volumn 44, Issue 11, 2014, Pages 1399-1408

  Royce, S G ^a,b   Lim, C X F ^a   Patel, K P ^b   Wang, B ^b   Samuel, C S ^b,c   Tang, M L K ^a,c,d  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Airway hyperesponsiveness; Airway remodelling; Allergic airways disease; Asthma; Intranasal; Serelaxin

Indexed keywords

COLLAGEN; IMMUNOGLOBULIN E; SERELAXIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; OVALBUMIN; RECOMBINANT PROTEIN; RELAXIN;

AIRWAY REMODELING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GOBLET CELL; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; LUNG LAVAGE; METAPLASIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RESPIRATORY TRACT ALLERGY; THICKNESS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG; PATHOLOGY; RESPIRATORY HYPERSENSITIVITY; RESPIRATORY TRACT MUCOSA;

ADMINISTRATION, INTRANASAL; AIRWAY REMODELING; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; GOBLET CELLS; IMMUNOGLOBULIN E; LUNG; METAPLASIA; MICE; OVALBUMIN; RECOMBINANT PROTEINS; RELAXIN; RESPIRATORY HYPERSENSITIVITY; RESPIRATORY MUCOSA;

EID: 84932182940     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12391     Document Type: Article

References (34)

1. Hargreave FE, Nair P. The definition and diagnosis of asthma. Clin Exp Allergy 2009; 39:1652-8.
2. Bush A, Zar HJ. WHO universal definition of severe asthma. Curr Opin Allergy Clin Immunol 2011; 11:115-21.
3. Tang ML, Wilson JW, Stewart AG, Royce SG. Airway remodelling in asthma: current understanding and implications for future therapies. Pharmacol Ther 2006; 112:474-88.
4. Royce SG, Tang ML. The effects of current therapies on airway remodeling in asthma and new possibilities for treatment and prevention. Curr Mol Pharmacol 2009; 2:169-81.
5. James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur Respir J 2007; 30:134-55.
6. Baldwin L, Roche WR. Does remodelling of the airway wall precede asthma? Paediatr Respir Rev 2002; 3:315-20.
7. Samuel CS, Hewitson TD, Unemori EN, Tang ML. Drugs of the future: the hormone relaxin. Cell Mol Life Sci 2007; 64:1539-57.
8. Bennett RG. Relaxin and its role in the development and treatment of fibrosis. Transl Res 2009; 154:1-6.
9. Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan M, Summers RJ. Relaxin family peptides and their receptors. Physiol Rev 2013; 93:405-80.
10. Royce SG, Miao YR, Lee M, Samuel CS, Tregear GW, Tang ML. Relaxin reverses airway remodeling and airway dysfunction in allergic airways disease. Endocrinology 2009; 150:2692-9.
11. Sherwood OD. Relaxin's physiological roles and other diverse actions. Endocr Rev 2004; 25:205-34.
12. Conrad KP. Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia. Semin Nephrol 2011; 31:15-32.
13. Masini E, Bani D, Bigazzi M, Mannaioni PF, Bani-Sacchi T. Effects of relaxin on mast cells. In vitro and in vivo studies in rats and guinea pigs. J Clin Invest 1994; 94:1974-80.
14. Bani D, Ballati L, Masini E, Bigazzi M, Sacchi TB. Relaxin counteracts asthma-like reaction induced by inhaled antigen in sensitized guinea pigs. Endocrinology 1997; 138:1909-15.
15. Kenyon NJ, Ward RW, Last JA. Airway fibrosis in a mouse model of airway inflammation. Toxicol Appl Pharmacol 2003; 186:90-100.
16. Unemori EN, Pickford LB, Salles AL et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98:2739-45.
17. Huang X, Gai Y, Yang N et al. Relaxin regulates myofibroblast contractility and protects against lung fibrosis. Am J Pathol 2011; 179:2751-65.
18. Tozzi CA, Poiani GJ, McHugh NA et al. Recombinant human relaxin reduces hypoxic pulmonary hypertension in the rat. Pulm Pharmacol Ther 2005; 18:346-53.
19. Samuel CS, Zhao C, Bathgate RA et al. Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. FASEB J 2003; 17:121-3.
20. Erikson MS, Unemori EN. Relaxin clinical trials in systemic sclerosis. In: Tregear GW, Ivell R, Bathgate RA, Wade JD, eds. Relaxin 2000: proceedings of the third international conference on relaxin and related peptides. Amsterdam: Kluwer, 2001:373-82.
21. Rottier BL, Rubin BK. Asthma medication delivery: mists and myths. Paediatr Respir Rev 2013; 14:112-8.
22. Temelkovski J, Hogan SP, Shepherd DP, Foster PS, Kumar RK. An improved murine model of asthma: selec-tive airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 1998; 53:849-56.
23. Locke NR, Royce SG, Wainewright JS, Samuel CS, Tang ML. Comparison of airway remodeling in acute, subacute, and chronic models of allergic airways disease. Am J Respir Cell Mol Biol 2007; 36:625-32.
24. Fiscus LC, Van Herpen J, Steeber DA, Tedder TF, Tang ML. L-Selectin is required for the development of airway hyperresponsiveness but not airway inflammation in a murine model of asthma. J Allergy Clin Immunol 2001; 107:1019-24.
25. Gallop PM, Paz MA. Posttranslational protein modifications, with special attention to collagen and elastin. Physiol Rev 1975; 55:418-87.
26. Royce SG, Li X, Tortorella S et al. Mechanistic insights into the contribution of epithelial damage to airway remodeling: novel therapeutic targets for asthma. Am J Respir Cell Mol Biol 2014; 50:180-92.
27. Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2013; (3):CD006922.
28. Hickey AJ. Back to the future: inhaled drug products. J Pharm Sci 2013; 102:1165-72.
29. Mookerjee I, Hewitson TD, Halls ML et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 2009; 23:1219-29.
30. Bennett RG, Heimann DG, Singh S, Simpson RL, Tuma DJ. Relaxin decreases the severity of established hepatic fibrosis in mice. Liver Int.
31. Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res 2003; 92:32-40.
32. Samuel CS, Cendrawan S, Gao XM et al. Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest 2011; 91:675-90.
33. Nistri S, Cinci L, Perna AM, Masini E, Mastroianni R, Bani D. Relaxin induces mast cell inhibition and reduces ventricular arrhythmias in a swine model of acute myocardial infarction. Pharm Res 2008; 57:43-8.
34. Royce SG, Sedjahtera A, Samuel CS, Tang ML. Combination therapy with relaxin and methylprednisolone augments the effects of either treatment alone in inhibiting subepithelial fibrosis in an experimental model of allergic airways disease. Clin Sci (Lond) 2013; 124:41-51.